Natural products to counteract the epidemic of cardiovascular and metabolic disorders

Molecules

Volumn 21, Issue 6, 2016, Pages

  Waltenberger, Birgit ^a   Mocan, Andrei ^b   Šmejkal, Karel ^c   Heiss, Elke H ^d   Atanasov, Atanas G ^d,e  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^d UNIVERSITY OF VIENNA   (Austria)

^e INSTITUTE OF GENETICS AND ANIMAL BREEDING   (Poland)

Author keywords

Biguanides; Cardiovascular disease; Coffee; Diabetes mellitus; Dietary constituents; Metabolic disorders; Molecular targets; Natural products; Statins

Indexed keywords

BIGUANIDE DERIVATIVE; BIOLOGICAL PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASES; DRUG DEVELOPMENT; HUMAN; MEDICINAL PLANT; METABOLIC DISEASES;

BIGUANIDES; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC DISEASES; PLANTS, MEDICINAL;

EID: 84976415537     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21060807     Document Type: Review

References (275)

1. Atanasov, A.G.; Waltenberger, B.; Pferschy-Wenzig, E.M.; Linder, T.; Wawrosch, C.; Uhrin, P.; Temml, V.; Wang, L.; Schwaiger, S.; Heiss, E.H.; et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol. Adv. 2015, 33, 1582-1614.
2. David, B.; Wolfender, J.-L.; Dias, D.A. The pharmaceutical industry and natural products: Historical status and new trends. Phytochem. Rev. 2015, 14, 299-315.
3. Amirkia, V.; Heinrich, M. Natural products and drug discovery: A survey of stakeholders in industry and academia. Front. Pharmacol. 2015, 6.
4. Efferth, T.; Zacchino, S.; Georgiev, M.I.; Liu, L.; Wagner, H.; Panossian, A. Nobel Prize for artemisinin brings phytotherapy into the spotlight. Phytomedicine 2015, 22, A1-A3.
5. Hertweck, C. Natural products as source of therapeutics against parasitic diseases. Angew. Chem. Int. Ed. Engl. 2015, 54, 14622-14624.
6. Cardoso, S.M.; Pereira, O.R.; Seca, A.M.; Pinto, D.C.; Silva, A.M. Seaweeds as preventive agents for cardiovascular diseases: From nutrients to functional foods. Mar. Drugs 2015, 13, 6838-6865.
7. Cornish, M.L.; Critchley, A.T.; Mouritsen, O.G. A role for dietary macroalgae in the amelioration of certain risk factors associated with cardiovascular disease. Phycologia 2015, 54, 649-666.
8. Tierney, M.S.; Croft, A.K.; Hayes, M. A review of antihypertensive and antioxidant activities in macroalgae. Bot. Mar. 2010, 53, 387-408.
9. Wijesekara, I.; Kim, S.K. Angiotensin-I-converting enzyme (ACE) inhibitors from marine resources: Prospects in the pharmaceutical industry. Mar. Drugs 2010, 8, 1080-1093.
10. Sperling, L.S.; Mechanick, J.I.; Neeland, I.J.; Herrick, C.J.; Després, J.-P.; Ndumele, C.E.; Vijayaraghavan, K.; Handelsman, Y.; Puckrein, G.A.; Araneta, M.R.G.; et al. The CardioMetabolic Health Alliance: Working toward a new care model for the metabolic syndrome. J. Am. Coll. Cardiol. 2015, 66, 1050-1067.
11. Huang, T.H.-W.; Teoh, A.W.; Lin, B.-L.; Lin, D.S.-H.; Roufogalis, B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol. Res. 2009, 60, 195-206.
12. Lusis, A.J. Atherosclerosis. Nature 2000, 407, 233-241.
13. World Health Organization (WHO). Global Status Report on Noncommunicable Diseases 2014; WHO: Geneva, Switzerland, 2014.
14. World Health Organization (WHO). Global Report on Diabetes 2016; WHO: Geneva, Switzerland, 2016.
15. Shaw, J.E.; Sicree, R.A.; Zimmet, P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87, 4-14.
16. Xiao, J. Natural polyphenols and diabetes: Understanding their mechanism of action. Curr. Med. Chem. 2015, 22, 2-3.
17. Cefalu, W.T.; Ye, J.; Wang, Z.Q. Efficacy of dietary supplementation with botanicals on carbohydrate metabolism in humans. Endocr. Metab. Immune Disord. Drug Targets 2008, 8, 78-81.
18. Dong, H.; Lu, F.-E.; Zhao, L. Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin. J. Integr. Med. 2012, 18, 152-160.
19. Heber, D. Herbs and atherosclerosis. Curr. Atheroscler. Rep. 2001, 3, 93-96.
20. World Health Organization (WHO). Traditional Medicine Strategy 2014-2023; WHO: Geneva, Switzerland, 2013.
21. Mashour, N.H.; Lin, G.I.; Frishman, W.H. Herbal medicine for the treatment of cardiovascular disease: Clinical considerations. Arch. Intern. Med. 1998, 158, 2225-2234.
22. Pittler, M.H.; Ernst, E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst. Rev. 2012, 11, CD003230.
23. Suter, A.; Bommer, S.; Rechner, J. Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: A review of 5 clinical studies. Adv. Ther. 2006, 23, 179-190.
24. Siebert, U.; Brach, M.; Sroczynski, G.; Berla, K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int. Angiol. 2002, 21, 305-315.
25. Rahman, K.; Lowe, G.M. Garlic and cardiovascular disease: A critical review. J. Nutr. 2006, 136, 736S-740S.
26. Sobenin, I.A.; Nedosugova, L.V.; Filatova, L.V.; Balabolkin, M.I.; Gorchakova, T.V.; Orekhov, A.N. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: The results of double-blinded placebo-controlled study. Acta Diabetol. 2008, 45, 1-6.
27. Al Disi, S.S.; Anwar, M.A.; Eid, A.H. Anti-hypertensive herbs and their mechanism of action: Part I. Front. Pharmacol. 2016, 6.
28. Kwak, J.S.; Kim, J.Y.; Paek, J.E.; Lee, Y.J.; Kim, H.R.; Park, D.S.; Kwon, O. Garlic powder intake and cardiovascular risk factors: A meta-analysis of randomized controlled clinical trials. Nutr. Res. Pract. 2014, 8, 644-654.
29. Stabler, S.N.; Tejani, A.M.; Huynh, F.; Fowkes, C. Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients. Cochrane Database Syst. Rev. 2012, 8, CD007653.
30. Zeng, T.; Guo, F.F.; Zhang, C.L.; Song, F.Y.; Zhao, X.L.; Xie, K.Q. A meta-analysis of randomized, double-blind, placebo-controlled trials for the effects of garlic on serum lipid profiles. J. Sci. Food Agric. 2012, 92, 1892-1902.
31. Okyar, A.; Can, A.; Akev, N.; Baktir, G.; Sütlüpinar, N. Effect of Aloe vera leaves on blood glucose level in type I and type II diabetic rat models. Phytother. Res. 2001, 15, 157-161.
32. Rajasekaran, S.; Ravi, K.; Sivagnanam, K.; Subramanian, S. Beneficial effects of Aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetes. Clin. Exp. Pharmacol. Physiol. 2006, 33, 232-237.
33. Alinejad-Mofrad, S.; Foadoddini, M.; Saadatjoo, S.A.; Shayesteh, M. Improvement of glucose and lipid profile status with Aloe vera in pre-diabetic subjects: A randomized controlled-trial. J. Diabetes Metab. Disord. 2015, 14.
34. Dick, W.R.; Fletcher, E.A.; Shah, S.A. Reduction of fasting blood glucose and hemoglobin A1c using oral Aloe vera: A meta-analysis. J. Altern. Complement. Med. 2016.
35. Devaraj, S.; Yimam, M.; Brownell, L.A.; Jialal, I.; Singh, S.; Jia, Q. Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab. Syndr. Relat. Disord. 2013, 11, 35-40.
36. Hashim, S.; Jan, A.; Marwat, K.B.; Khan, M.A. Phytochemistry and medicinal properties of Ammi visnaga (Apiacae). Pak. J. Bot. 2014, 46, 861-867.
37. Durate, J.; Vallejo, I.; Perez-Vizcaino, F.; Jimenez, R.; Zarzuelo, A.; Tamargo, J. Effects of visnadine on rat isolated vascular smooth muscles. Planta Med. 1997, 63, 233-236.
38. Duarte, J.; Perez-Vizcaino, F.; Torres, A.I.; Zarzuelo, A.; Jimenez, J.; Tamargo, J. Vasodilator effects of visnagin in isolated rat vascular smooth muscle. Eur. J. Pharmacol. 1995, 286, 115-122.
39. Hao, P.-P.; Jiang, F.; Chen, Y.-G.; Yang, J.; Zhang, K.; Zhang, M.-X.; Zhang, C.; Zhao, Y.-X.; Zhang, Y. Traditional Chinese medication for cardiovascular disease. Nat. Rev. Cardiol. 2015, 12, 115-122.
40. Kim, D.-W.; Yokozawa, T.; Hattori, M.; Kadota, S.; Namba, T. Effects of aqueous extracts of Apocynum venetum leaves on spontaneously hypertensive, renal hypertensive and NaCl-fed-hypertensive rats. J. Ethnopharmacol. 2000, 72, 53-59.
41. Xie, W.; Zhang, X.; Wang, T.; Hu, J. Botany, traditional uses, phytochemistry and pharmacology of Apocynum venetum L. (Luobuma): A review. J. Ethnopharmacol. 2012, 141, 1-8.
42. Wang, W.; Liang, X.; Fu, D.; Tie, R.; Xing, W.; Ji, L.; Liu, F.; Zhang, H.; Li, R. Apocynum venetum leaf attenuates myocardial ischemia/reperfusion injury by inhibiting oxidative stress. Am. J. Chin. Med. 2015, 43, 71-85.
43. Aggarwal, S.; Shailendra, G.; Ribnicky, D.M.; Burk, D.; Karki, N.; Qingxia Wang, M.S. An extract of Artemisia dracunculus L. stimulates insulin secretion from β cells, activates AMPK and suppresses inflammation. J. Ethnopharmacol. 2015, 170, 98-105.
44. Watcho, P.; Stavniichuk, R.; Tane, P.; Shevalye, H.; Maksimchyk, Y.; Pacher, P.; Obrosova, I.G. Evaluation of PMI-5011, an ethanolic extract of Artemisia dracunculus L., on peripheral neuropathy in streptozotocin-diabetic mice. Int. J. Mol. Med. 2011, 27, 299-307.
45. Watcho, P.; Stavniichuk, R.; Ribnicky, D.M.; Raskin, I.; Obrosova, I.G. High-fat diet-induced neuropathy of prediabetes and obesity: Effect of PMI-5011, an ethanolic extract of Artemisia dracunculus L. Mediat. Inflamm. 2010, 2010.
46. Hamza, N.; Berke, B.; Cheze, C.; Marais, S.; Lorrain, S.; Abdouelfath, A.; Lassalle, R.; Carles, D.; Gin, H.; Moore, N. Effect of Centaurium erythraea Rafn, Artemisia herba-alba Asso and Trigonella foenum-graecum L. on liver fat accumulation in C57BL/6J mice with high-fat diet-induced type 2 diabetes. J. Ethnopharmacol. 2015, 171, 4-11.
47. Boudjelal, A.; Siracusa, L.; Henchiri, C.; Sarri, M.; Abderrahim, B.; Baali, F.; Ruberto, G. Antidiabetic effects of aqueous infusions of Artemisia herba-alba and Ajuga iva in alloxan-induced diabetic rats. Planta Med. 2015, 81, 696-704.
48. Hamza, N.; Berke, B.; Cheze, C.; Le Garrec, R.; Lassalle, R.; Agli, A.N.; Robinson, P.; Gin, H.; Moore, N. Treatment of high fat diet induced type 2 diabetes in C57BL/6J mice by two medicinal plants used in traditional treatment of diabetes in the east of Algeria. J. Ethnopharmacol. 2011, 133, 931-933.
49. Al-Shamaony, L.; al-Khazraji, S.M.; Twaij, H.A. Hypoglycaemic effect of Artemisia herba alba. II. Effect of a valuable extract on some blood parameters in diabetic animals. J. Ethnopharmacol. 1994, 43, 167-171.
50. Hamza, N.; Berke, B.; Cheze, C.; Agli, A.N.; Robinson, P.; Gin, H.; Moore, N. Prevention of type 2 diabetes induced by high fat diet in the C57BL/6J mouse by two medicinal plants used in traditional treatment of diabetes in the east of Algeria. J. Ethnopharmacol. 2010, 128, 513-518.
51. Kawano, A.; Nakamura, H.; Hata, S.-I.; Minakawa, M.; Miura, Y.; Yagasaki, K. Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine 2009, 16, 437-443.
52. Son, M.J.; Minakawa, M.; Miura, Y.; Yagasaki, K. Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice. Eur. J. Nutr. 2013, 52, 1607-1619.
53. Mazibuko, S.E.; Joubert, E.; Johnson, R.; Louw, J.; Opoku, A.R.; Muller, C.J. Aspalathin improves glucose and lipid metabolism in 3T3-L1 adipocytes exposed to palmitate. Mol. Nutr. Food Res. 2015, 59, 2199-2208.
54. Ku, S.K.; Kwak, S.; Kim, Y.; Bae, J.S. Aspalathin and nothofagin from rooibos (Aspalathus linearis) inhibits high glucose-induced inflammation in vitro and in vivo. Inflammation 2015, 38, 445-455.
55. Chen, W.; Lai, Y.; Wang, L.; Xia, Y.; Chen, W.; Zhao, X.; Yu, M.; Li, Y.; Zhang, Y.; Ye, H. Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice. J. Diabetes Complicat. 2015, 29, 164-175.
56. Kim, J.; Moon, E.; Kwon, S. Effect of Astragalus membranaceus extract on diabetic nephropathy. Endocrinol. Diabetes Metab. Case Rep. 2014, 2014.
57. -/- mice induced by hyperlipaemia. Evid. Based Complement. Altern. Med. 2015, 2015.
58. Zhao, P.; Wang, Y.; Zeng, S.; Lu, J.; Jiang, T.-M.; Li, Y.-M. Protective effect of astragaloside IV on lipopolysaccharide-induced cardiac dysfunction via downregulation of inflammatory signaling in mice. Immunopharmacol. Immunotoxicol. 2015, 37, 428-433.
59. Lu, Y.; Li, S.; Wu, H.; Bian, Z.; Xu, J.; Gu, C.; Chen, X.; Yang, D. Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells. Int. J. Mol. Med. 2015, 36, 1223-1232.
60. Bai, Y.; Lu, P.; Han, C.; Yu, C.; Chen, M.; He, F.; Yi, D.; Wu, L. Hydroxysafflor yellow A (HSYA) from flowers of Carthamus tinctorius L. and its vasodilatation effects on pulmonary artery. Molecules 2012, 17, 14918-14927.
61. Nie, P.H.; Zhang, L.; Zhang, W.H.; Rong, W.F.; Zhi, J.M. The effects of hydroxysafflor yellow A on blood pressure and cardiac function. J. Ethnopharmacol. 2012, 139, 746-750.
62. Chen, J.; Deng, J.; Zhang, Y.; Yang, J.; He, Y.; Fu, W.; Xing, P.; Wan, H.T. Lipid-lowering effects of Danhong injection on hyperlipidemia rats. J. Ethnopharmacol. 2014, 154, 437-442.
63. Li, L.; Dong, P.; Hou, C.; Cao, F.; Sun, S.; He, F.; Song, Y.; Li, S.; Bai, Y.; Zhu, D. Hydroxysafflor yellow A (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats. J. Ethnopharmacol. 2016, 186, 224-233.
64. L-NAME-induced hypertensive rats via restoration of eNOS and AT1R expression. Nutrients 2016, 8.
65. Sefi, M.; Fetoui, H.; Lachkar, N.; Tahraoui, A.; Lyoussi, B.; Boudawara, T.; Zeghal, N. Centaurium erythrea (Gentianaceae) leaf extract alleviates streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. J. Ethnopharmacol. 2011, 135, 243-250.
66. Stefkov, G.; Miova, B.; Dinevska-Kjovkarovska, S.; Stanoeva, J.P.; Stefova, M.; Petrusevska, G.; Kulevanova, S. Chemical characterization of Centaurium erythrea L. and its effects on carbohydrate and lipid metabolism in experimental diabetes. J. Ethnopharmacol. 2014, 152, 71-77.
67. Eddouks, M.; Bidi, A.; El Bouhali, B.; Hajji, L.; Zeggwagh, N.A. Antidiabetic plants improving insulin sensitivity. J. Pharm. Pharmacol. 2014, 66, 1197-1214.
68. Yan, Y.-M.; Fang, P.; Yang, M.-T.; Li, N.; Lu, Q.; Cheng, Y.-X. Anti-diabetic nephropathy compounds from Cinnamomum cassia. J. Ethnopharmacol. 2015, 165, 141-147.
69. Medagama, A.B. The glycaemic outcomes of cinnamon, a review of the experimental evidence and clinical trials. Nutr. J. 2015, 14.
70. Crawford, P. Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: A randomized, controlled trial. J. Am. Board Fam. Med. 2009, 22, 507-512.
71. Mirfeizi, M.; Mehdizadeh Tourzani, Z.; Mirfeizi, S.Z.; Asghari Jafarabadi, M.; Rezvani, H.R.; Afzali, M.; Gholami, M.J. Controlling diabetes mellitus type 2 with herbal medicines: A triple blind, randomized clinical trial of efficacy and safety. J. Diabetes 2015.
72. Ríos, J.L.; Francini, F.; Schinella, G.R. Natural products for the treatment of type 2 diabetes mellitus. Planta Med. 2015, 81, 975-994.
73. Whitfield, P.; Parry-Strong, A.; Walsh, E.; Weatherall, M.; Krebs, J.D. The effect of a cinnamon-, chromium- and magnesium-formulated honey on glycaemic control, weight loss and lipid parameters in type 2 diabetes: An open-label cross-over randomised controlled trial. Eur. J. Nutr. 2016, 55, 1123-1131.
74. Beejmohun, V.; Peytavy-Izard, M.; Mignon, C.; Muscente-Paque, D.; Deplanque, X.; Ripoll, C.; Chapal, N. Acute effect of Ceylon cinnamon extract on postprandial glycemia: Alpha-amylase inhibition, starch tolerance test in rats, and randomized crossover clinical trial in healthy volunteers. BMC Complement. Altern. Med. 2014, 14.
75. Frishman, W.H.; Beravol, P.; Carosella, C. Alternative and complementary medicine for preventing and treating cardiovascular disease. Dis. Mon. 2009, 55, 121-192.
76. Ojha, S.K.; Nandave, M.; Arora, S.; Mehra, R.D.; Joshi, S.; Narang, R.; Arya, D.S. Effect of Commiphora mukul extract on cardiac dysfunction and ventricular function in isoproterenol-induced myocardial infarction. Indian J. Exp. Biol. 2008, 46, 646-652.
77. Yuan, L.; Tu, D.; Ye, X.; Wu, J. Hypoglycemic and hypocholesterolemic effects of Coptis chinensis Franch inflorescence. Plant Foods Hum. Nutr. 2006, 61, 139-144.
78. Dong, H.; Wang, J.-H.; Lu, F.-E.; Xu, L.-J.; Gong, Y.-L.; Zou, X. Jiaotai Pill enhances insulin signaling through phosphatidylinositol 3-kinase pathway in skeletal muscle of diabetic rats. Chin. J. Integr. Med. 2013, 19, 668-674.
79. Yang, Z.; Wang, L.; Zhang, F.; Li, Z. Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches. BMC Complement. Altern. Med. 2015, 15.
80. Eidi, M.; Eidi, A.; Saeidi, A.; Molanaei, S.; Sadeghipour, A.; Bahar, M.; Bahar, K. Effect of coriander seed (Coriandrum sativum L.) ethanol extract on insulin release from pancreatic beta cells in streptozotocin-induced diabetic rats. Phytother. Res. 2009, 23, 404-406.
81. Dhanapakiam, P.; Joseph, J.M.; Ramaswamy, V.K.; Moorthi, M.; Kumar, A.S. The cholesterol lowering properties of coriander seeds (Coriandrum sativum): Mechanism of action. J. Environ. Biol. 2008, 29, 53-56.
82. Sreelatha, S.; Inbavalli, R. Antioxidant, antihyperglycemic, and antihyperlipidemic effects of Coriandrum sativum leaf and stem in alloxan-induced diabetic rats. J. Food Sci. 2012, 77, T119-T123.
83. Aissaoui, A.; Zizi, S.; Israili, Z.H.; Lyoussi, B. Hypoglycemic and hypolipidemic effects of Coriandrum sativum L. in Meriones shawi rats. J. Ethnopharmacol. 2011, 137, 652-661.
84. Chang, W.-T.; Dao, J.; Shao, Z.-H. Hawthorn: Potential roles in cardiovascular disease. Am. J. Chin. Med. 2005, 33, 1-10.
85. Chrysant, S.G. The clinical significance and costs of herbs and food supplements used by complementary and alternative medicine for the treatment of cardiovascular diseases and hypertension. J. Hum. Hypertens. 2016, 30, 1-6.
86. Asher, G.N.; Viera, A.J.; Weaver, M.A.; Dominik, R.; Caughey, M.; Hinderliter, A.L. Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: A randomized, controlled cross-over trial. BMC Complement. Altern. Med. 2012, 12.
87. Pittler, M.H.; Guo, R.; Ernst, E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst. Rev. 2008, 1, CD005312.
88. Bundy, R.; Walker, A.F.; Middleton, R.W.; Wallis, C.; Simpson, H.C.R. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: A randomized, double blind placebo controlled trial. Phytomedicine 2008, 15, 668-675.
89. Ben Salem, M.; Affes, H.; Ksouda, K.; Dhouibi, R.; Sahnoun, Z.; Hammami, S.; Zeghal, K.M. Pharmacological studies of artichoke leaf extract and their health benefits. Plant Foods Hum. Nutr. 2015, 70, 441-453.
90. Maghrani, M.; Zeggwagh, N.-A.; Lemhadri, A.; El Amraoui, M.; Michel, J.-B.; Eddouks, M. Study of the hypoglycaemic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. J. Ethnopharmacol. 2004, 91, 309-316.
91. Eddouks, M.; Maghrani, M. Phlorizin-like effect of Fraxinus excelsior in normal and diabetic rats. J. Ethnopharmacol. 2004, 94, 149-154.
92. Gomez-Garcia, F.; Flanagan, J.; García-Molina, O.; Vilaplana-Vivo, V.; García-Carrillo, N.; Berthon, P.F.; Bily, A.; Roller, M.; Ortega, V.V.; Issaly, N. Preventive effect of a Fraxinus excelsior L seeds/fruits extract on hepatic steatosis in obese type 2 diabetic mice. J. Diabetes Metab. 2015, 6.
93. Visen, P.; Saraswat, B.; Visen, A.; Roller, M.; Bily, A.; Mermet, C.; He, K.; Bai, N.; Lemaire, B.; Lafay, S.; et al. Acute effects of Fraxinus excelsior L. seed extract on postprandial glycemia and insulin secretion on healthy volunteers. J. Ethnopharmacol. 2009, 126, 226-232.
94. Bai, N.; He, K.; Ibarra, A.; Bily, A.; Roller, M.; Chen, X.; Rülh, R. Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARα activation activity. J. Nat. Prod. 2010, 73, 2-6.
95. Zulet, M.A.; Navas-Carretero, S.; Lara y Sanchez, D.; Abete, I.; Flanagan, J.; Issaly, N.; Fanca-Berthon, P.; Bily, A.; Roller, M.; Martinez, J.A. A Fraxinus excelsior L. seeds/fruits extract benefits glucose homeostasis and adiposity related markers in elderly overweight/obese subjects: A longitudinal, randomized, crossover, double-blind, placebo-controlled nutritional intervention study. Phytomedicine 2014, 21, 1162-1169.
96. Bedekar, A.; Shah, K.; Koffas, M. Natural products for type II diabetes treatment. Adv. Appl. Microbiol. 2010, 71, 21-73.
97. Perla, V.; Jayanty, S.S. Biguanide related compounds in traditional antidiabetic functional foods. Food Chem. 2013, 138, 1574-1580.
98. Witters, L.A. The blooming of the French lilac. J. Clin. Investig. 2001, 108, 1105-1107.
99. Gardner, C.D.; Zehnder, J.L.; Rigby, A.J.; Nicholus, J.R.; Farquhar, J.W. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: A randomized clinical trial. Blood Coagul. Fibrinolysis 2007, 18, 787-793.
100. Lu, Q.; Zuo, W.-Z.; Ji, X.-J.; Zhou, Y.-X.; Liu, Y.-Q.; Yao, X.-Q.; Zhou, X.-Y.; Liu, Y.-W.; Zhang, F.; Yin, X.-X. Ethanolic Ginkgo biloba leaf extract prevents renal fibrosis through Akt/mTOR signaling in diabetic nephropathy. Phytomedicine 2015, 22, 1071-1078.
101. Erukainure, O.L.; Ajiboye, J.A.; Lawal, B.A.; Obode, O.C.; Okoro, E.E.; Amisu-Tugbobo, A.O.; Zaruwa, M.Z. Alterations in atherogenic indices and hypolipidemic effect of soybean oil in normocholesteremic rats. Comp. Clin. Pathol. 2016, 25, 75-78.
102. Kwon, D.Y.; Daily, J.W.; Kim, H.J.; Park, S. Antidiabetic effects of fermented soybean products on type 2 diabetes. Nutr. Res. 2010, 30, 1-13.
103. Jiang, H.; Tong, Y.; Yan, D.; Jia, S.; Ostenson, C.G.; Chen, Z. The soybean peptide vglycin preserves the diabetic beta-cells through improvement of proliferation and inhibition of apoptosis. Sci. Rep. 2015, 5.
104. Fuhrman, B.; Volkova, N.; Kaplan, M.; Presser, D.; Attias, J.; Hayek, T.; Aviram, M. Antiatherosclerotic effects of licorice extract supplementation on hypercholesterolemic patients: Increased resistance of LDL to atherogenic modifications, reduced plasma lipid levels, and decreased systolic blood pressure. Nutrition 2002, 18, 268-273.
105. Chang, W.-C.; Jia, H.; Aw, W.; Saito, K.; Hasegawa, S.; Kato, H. Beneficial effects of soluble dietary Jerusalem artichoke (Helianthus tuberosus) in the prevention of the onset of type 2 diabetes and non-alcoholic fatty liver disease in high-fructose diet-fed rats. Br. J. Nutr. 2014, 112, 709-717.
106. Gambero, A.; Ribeiro, M.L. The positive effects of yerba maté (Ilex paraguariensis) in obesity. Nutrients 2015, 7, 730-750.
107. De Moraes Pontilho, P.; Nunes da Costa Teixeira, A.M.; Yuan, C.; Alves Luzia, L.; Markowicz Bastos, D.H.; Rondó, P.H. Yerba mate (Ilex paraguariensis A. St. Hil) and risk factors for cardiovascular diseases. J. Food Nutr. Res. 2015, 3, 182-190.
108. Cardozo, E.L., Jr.; Morand, C. Interest of mate (Ilex paraguariensis A. St.-Hil.) as a new natural functional food to preserve human cardiovascular health - A review. J. Funct. Foods 2016, 21, 440-454.
109. Chang, C.L.T.; Lin, Y.; Bartolome, A.P.; Chen, Y.-C.; Chiu, S.-C.; Yang, W.-C. Herbal therapies for type 2 diabetes mellitus: Chemistry, biology, and potential application of selected plants and compounds. Evid. Based Complement. Alternat. Med. 2013, 2013.
110. Kim, S.-Y.; Oh, M.-R.; Kim, M.-G.; Chae, H.-J.; Chae, S.-W. Anti-obesity effects of yerba mate (Ilex Paraguariensis): A randomized, double-blind, placebo-controlled clinical trial. BMC Complement. Altern. Med. 2015, 15.
111. Yu, S.; Yue, S.w.; Liu, Z.; Zhang, T.; Xiang, N.; Fu, H. Yerba mate (Ilex paraguariensis) improves microcirculation of volunteers with high blood viscosity: A randomized, double-blind, placebo-controlled trial. Exp. Gerontol. 2015, 62, 14-22.
112. Luo, Q.; Cai, Y.; Yan, J.; Sun, M.; Corke, H. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum. Life Sci. 2004, 76, 137-149.
113. Zhao, R.; Jin, R.; Chen, Y.; Han, F.-m. Hypoglycemic and hypolipidemic effects of Lycium barbarum polysaccharide in diabetic rats. Chin. Herb. Med. 2015, 7, 310-315.
114. Amagase, H.; Nance, D.M. A randomized, double-blind, placebo-controlled, clinical study of the general effects of a standardized Lycium barbarum (Goji) juice, GoChi™. J. Altern. Complement. Med. 2008, 14, 403-412.
115. Zhang, X.; Yang, X.; Lin, Y.; Suo, M.; Gong, L.; Chen, J.; Hui, R. Anti-hypertensive effect of Lycium barbarum L. with down-regulated expression of renal endothelial lncRNA sONE in a rat model of salt-sensitive hypertension. Int. J. Clin. Exp. Pathol. 2015, 8, 6981-6987.
116. Lu, S.-P.; Zhao, P.-T. Chemical characterization of Lycium barbarum polysaccharides and their reducing myocardial injury in ischemia/reperfusion of rat heart. Int. J. Biol. Macromol. 2010, 47, 681-684.
117. Ming, M.; Guanhua, L.; Zhanhai, Y.; Guang, C.; Xuan, Z. Effect of the Lycium barbarum polysaccharides administration on blood lipid metabolism and oxidative stress of mice fed high-fat diet in vivo. Food Chem. 2009, 113, 872-877.
118. Cai, H.; Liu, F.; Zuo, P.; Huang, G.; Song, Z.; Wang, T.; Lu, H.; Guo, F.; Han, C.; Sun, G. Practical application of antidiabetic efficacy of Lycium barbarum polysaccharide in patients with type 2 diabetes. Med. Chem. 2015, 11, 383-390.
119. Zhu, X.; Hu, S.; Zhu, L.; Ding, J.; Zhou, Y.; Li, G. Effects of Lycium barbarum polysaccharides on oxidative stress in hyperlipidemic mice following chronic composite psychological stress intervention. Mol. Med. Rep. 2015, 11, 3445-3450.
120. Mishra, A.; Gautam, S.; Pal, S.; Mishra, A.; Rawat, A.K.; Maurya, R.; Srivastava, A.K. Effect of Momordica charantia fruits on streptozotocin-induced diabetes mellitus and its associated complications. Int. J. Pharm. Pharm. Sci. 2015, 7, 356-363.
121. Yang, S.J.; Choi, J.M.; Park, S.E.; Rhee, E.J.; Lee, W.Y.; Oh, K.W.; Park, S.W.; Park, C.-Y. Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats. J. Nutr. Biochem. 2015, 26, 234-240.
122. Singab, A.N.B.; El-Beshbishy, H.A.; Yonekawa, M.; Nomura, T.; Fukai, T. Hypoglycemic effect of Egyptian Morus alba root bark extract: Effect on diabetes and lipid peroxidation of streptozotocin-induced diabetic rats. J. Ethnopharmacol. 2005, 100, 333-338.
123. Hunyadi, A.; Martins, A.; Hsieh, T.-J.; Seres, A.; Zupkó, I. Chlorogenic acid and rutin play a major role in the in vivo anti-diabetic activity of Morus alba leaf extract on type II diabetic rats. PLoS ONE 2012, 7, e50619.
124. Butt, M.S.; Nazir, A.; Sultan, M.T.; Schroën, K. Morus alba L. nature's functional tonic. Trends Food Sci. Technol. 2008, 19, 505-512.
125. Cai, S.; Sun, W.; Fan, Y.; Guo, X.; Xu, G.; Xu, T.; Hou, Y.; Zhao, B.; Feng, X.; Liu, T. Effect of mulberry leaf (Folium mori) on insulin resistance via IRS-1/PI3K/Glut-4 signalling pathway in type 2 diabetes mellitus rats. Pharm. Biol. 2016.
126. Mahmoud, A.M.; Abd El-Twab, S.M.; Abdel-Reheim, E.S. Consumption of polyphenol-rich Morus alba leaves extract attenuates early diabetic retinopathy: The underlying mechanism. Eur. J. Nutr. 2016.
127. Phimarn, W.; Wichaiyo, K.; Silpsavikul, K.; Sungthong, B.; Saramunee, K. A meta-analysis of efficacy of Morus alba Linn. to improve blood glucose and lipid profile. Eur. J. Nutr. 2016.
128. Heshmati, J.; Namazi, N. Effects of black seed (Nigella sativa) on metabolic parameters in diabetes mellitus: A systematic review. Complement. Ther. Med. 2015, 23, 275-282.
129. Heshmati, J.; Namazi, N.; Memarzadeh, M.-R.; Taghizadeh, M.; Kolahdooz, F. Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Food Res. Int. 2015, 70, 87-93.
130. Kaatabi, H.; Bamosa, A.O.; Badar, A.; Al-Elq, A.; Abou-Hozaifa, B.; Lebda, F.; Al-Khadra, A.; Al-Almaie, S. Nigella sativa improves glycemic control and ameliorates oxidative stress in patients with type 2 diabetes mellitus: Placebo controlled participant blinded clinical trial. PLoS ONE 2015, 10, e0113486.
131. Mahdavi, R.; Namazi, N.; Alizadeh, M.; Farajnia, S. Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: A randomized controlled clinical trial. Food Funct. 2015, 6, 2041-2048.
132. Asgary, S.; Sahebkar, A.; Goli-Malekabadi, N. Ameliorative effects of Nigella sativa on dyslipidemia. J. Endocrinol. Investig. 2015, 38, 1039-1046.
133. Husain, I.; Chander, R.; Saxena, J.K.; Mahdi, A.A.; Mahdi, F. Antidyslipidemic effect of Ocimum sanctum leaf extract in streptozotocin induced diabetic rats. Indian J. Clin. Biochem. 2015, 30, 72-77.
134. Thadani, S.; Salman, M.T.; Tewari, S.; Singh, S.; Bhagchandani, D.; Ahmad, A. Renoprotective effect of Ocimum sanctum in comparison with olmesartan medoxomil and pitavastatin in metformin treated diabetic rats. Int. J. Pharm. Sci. Res. 2015, 6, 4433-4441.
135. El, S.N.; Karakaya, S. Olive tree (Olea europaea) leaves: Potential beneficial effects on human health. Nutr. Rev. 2009, 67, 632-638.
136. Poudyal, H.; Campbell, F.; Brown, L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J. Nutr. 2010, 140, 946-953.
137. Susalit, E.; Agus, N.; Effendi, I.; Tjandrawinata, R.R.; Nofiarny, D.; Perrinjaquet-Moccetti, T.; Verbruggen, M. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: Comparison with captopril. Phytomedicine 2011, 18, 251-258.
138. Efentakis, P.; Iliodromitis, E.K.; Mikros, E.; Papachristodoulou, A.; Dagres, N.; Skaltsounis, A.-L.; Andreadou, I. Effects of the olive tree leaf constituents on myocardial oxidative damage and atherosclerosis. Planta Med. 2015, 81, 648-654.
139. Wainstein, J.; Ganz, T.; Boaz, M.; Bar Dayan, Y.; Dolev, E.; Kerem, Z.; Madar, Z. Olive leaf extract as a hypoglycemic agent in both human diabetic subjects and in rats. J. Med. Food 2012, 15, 605-610.
140. Lepore, S.M.; Morittu, V.M.; Celano, M.; Trimboli, F.; Oliverio, M.; Procopio, A.; Di Loreto, C.; Damante, G.; Britti, D.; Bulotta, S.; et al. Oral administration of oleuropein and its semisynthetic peracetylated derivative prevents hepatic steatosis, hyperinsulinemia, and weight gain in mice fed with high fat cafeteria diet. Int. J. Endocrinol. 2015, 2015.
141. Perona, J.S.; Cañizares, J.; Montero, E.; Sánchez-Domínguez, J.M.; Catalá, A.; Ruiz-Gutiérrez, V. Virgin olive oil reduces blood pressure in hypertensive elderly subjects. Clin. Nutr. 2004, 23, 1113-1121.
142. Quintieri, A.M.; Filice, E.; Amelio, D.; Pasqua, T.; Lupi, F.R.; Scavello, F.; Cantafio, P.; Rocca, C.; Lauria, A.; Penna, C.; et al. The innovative "Bio-Oil Spread" prevents metabolic disorders and mediates preconditioning-like cardioprotection in rats. Nutr. Metab. Cardiovasc. Dis. 2016.
143. Zhang, Y.-G.; Zhang, H.-G.; Zhang, G.-Y.; Fan, J.-S.; Li, X.-H.; Liu, Y.-H.; Li, S.-H.; Lian, X.-M.; Tang, Z. Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin. Exp. Pharmacol. Physiol. 2008, 35, 1238-1244.
144. Bello, C.T.; Turner, L.W. Reserpine as an antihypertensive in the outpatient clinic: A double-blind clinical study. Am. J. Med. Sci. 1956, 232, 194-197.
145. Shamon, S.D.; Perez, M.I. Blood pressure lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst. Rev. 2009, 4, CD007655.
146. Yu, L.; Qin, Y.; Wang, Q.; Zhang, L.; Liu, Y.; Wang, T.; Huang, L.; Wu, L.; Xiong, H. The efficacy and safety of Chinese herbal medicine, Rhodiola formulation in treating ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials. Complement. Ther. Med. 2014, 22, 814-825.
147. Wu, T.; Zhou, H.; Jin, Z.; Bi, S.; Yang, X.; Yi, D.; Liu, W. Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage to cellular proteins. Eur. J. Pharmacol. 2009, 613, 93-99.
148. Sinkovic, A.; Suran, D.; Lokar, L.; Fliser, E.; Skerget, M.; Novak, Z.; Knez, Z. Rosemary extracts improve flow-mediated dilatation of the brachial artery and plasma PAI-1 activity in healthy young volunteers. Phytother. Res. 2011, 25, 402-407.
149. Posadas, S.J.; Caz, V.; Largo, C.; de la Gándara, B.; Matallanas, B.; Reglero, G.; de Miguel, E. Protective effect of supercritical fluid rosemary extract, Rosmarinus officinalis, on antioxidants of major organs of aged rats. Exp. Gerontol. 2009, 44, 383-389.
150. Vanscheidt, W.; Jost, V.; Wolna, P.; Lücker, P.W.; Müller, A.; Theurer, C.; Patz, B.; Grützner, K.I. Efficacy and safety of a butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung 2002, 52, 243-250.
151. Ciocoiu, M.; Mirón, A.; Mares, L.; Tutunaru, D.; Pohaci, C.; Groza, M.; Badescu, M. The effects of Sambucus nigra polyphenols on oxidative stress and metabolic disorders in experimental diabetes mellitus. J. Physiol. Biochem. 2009, 65, 297-304.
152. Bhattacharya, S.; Christensen, K.B.; Olsen, L.C.B.; Christensen, L.P.; Grevsen, K.; Færgeman, N.J.; Kristiansen, K.; Young, J.F.; Oksbjerg, N. Bioactive components from flowers of Sambucus nigra L. increase glucose uptake in primary porcine myotube cultures and reduce fat accumulation in Caenorhabditis elegans. J. Agric. Food Chem. 2013, 61, 11033-11040.
153. Christensen, K.B.; Petersen, R.K.; Kristiansen, K.; Christensen, L.P. Identification of bioactive compounds from flowers of black elder (Sambucus nigra L.) that activate the human peroxisome proliferator-activated receptor (PPAR) gamma. Phytother. Res. 2010, 24, S129-S132.
154. Li, L.; Zhou, X.; Li, N.; Sun, M.; Lv, J.; Xu, Z. Herbal drugs against cardiovascular disease: Traditional medicine and modern development. Drug Discov. Today 2015, 20, 1074-1086.
155. Chun, J.N.; Cho, M.; So, I.; Jeon, J.-H. The protective effects of Schisandra chinensis fruit extract and its lignans against cardiovascular disease: A review of the molecular mechanisms. Fitoterapia 2014, 97, 224-233.
156. Liu, H.; Wu, C.; Wang, S.; Gao, S.; Liu, J.; Dong, Z.; Zhang, B.; Liu, M.; Sun, X.; Guo, P. Extracts and lignans of Schisandra chinensis fruit alter lipid and glucose metabolism in vivo and in vitro. J. Funct. Foods 2015, 19, 296-307.
157. Zhang, M.; Liu, M.; Xiong, M.; Gong, J.; Tan, X. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy. J. Ethnopharmacol. 2012, 141, 111-118.
158. Li, J.; Wang, J.; Shao, J.-Q.; Du, H.; Wang, Y.-T.; Peng, L. Effect of Schisandra chinensis on interleukins, glucose metabolism, and pituitary-adrenal and gonadal axis in rats under strenuous swimming exercise. Chin. J. Integr. Med. 2015, 21, 43-48.
159. Huseini, H.F.; Larijani, B.; Heshmat, R.; Fakhrzadeh, H.; Radjabipour, B.; Toliat, T.; Raza, M. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial. Phytother. Res. 2006, 20, 1036-1039.
160. Tamayo, C.; Diamond, S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr. Cancer Ther. 2007, 6, 146-157.
161. Derosa, G.; D'Angelo, A.; Maffioli, P. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. Clin. Nutr. 2015.
162. Ebrahimpour Koujan, S.; Gargari, B.P.; Mobasseri, M.; Valizadeh, H.; Asghari-Jafarabadi, M. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: A randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine 2015, 22, 290-296.
163. Di Pierro, F.; Bellone, I.; Rapacioli, G.; Putignano, P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab. Syndr. Obes. 2015, 8, 89-96.
164. Bhasker, S.; Madhav, H.; Chinnamma, M. Molecular evidence of insulinomimetic property exhibited by steviol and stevioside in diabetes induced L6 and 3T3L1 cells. Phytomedicine 2015, 22, 1037-1044.
165. Ritu, M.; Nandini, J. Nutritional composition of Stevia rebaudiana - A sweet herb and its hypoglycaemic and hypolipidaemic effect on patients with non insulin dependent diabetes mellitus. J. Sci. Food Agric. 2016.
166. Asemi, Z.; Khorrami-Rad, A.; Alizadeh, S.A.; Shakeri, H.; Esmaillzadeh, A. Effects of synbiotic food consumption on metabolic status of diabetic patients: A double-blind randomized cross-over controlled clinical trial. Clin. Nutr. 2014, 33, 198-203.
167. Saravanan, R.; Vengatash babu, K.; Ramachandran, V. Effect of rebaudioside A, a diterpenoid on glucose homeostasis in STZ-induced diabetic rats. J. Physiol. Biochem. 2012, 68, 421-431.
168. Fuller, S.; Stephens, J.M. Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: Mechanisms of actions and potential effects on metabolic syndrome. Adv. Nutr. 2015, 6, 189-197.
169. Gaddam, A.; Galla, C.; Thummisetti, S.; Marikanty, R.K.; Palanisamy, U.D.; Rao, P.V. Role of fenugreek in the prevention of type 2 diabetes mellitus in prediabetes. J. Diabetes Metab. Disord. 2015, 14.
170. Basu, A.; Du, M.; Leyva, M.J.; Sanchez, K.; Betts, N.M.; Wu, M.; Aston, C.E.; Lyons, T.J. Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. J. Nutr. 2010, 140, 1582-1587.
171. Johnson, M.H.; de Mejia, E.G. Phenolic compounds from fermented berry beverages modulated gene and protein expression to increase insulin secretion from pancreatic beta-cells in vitro. J. Agric. Food Chem. 2016, 64, 2569-2581.
172. Johnson, M.H.; de Mejia, E.G.; Fan, J.; Lila, M.A.; Yousef, G.G. Anthocyanins and proanthocyanidins from blueberry-blackberry fermented beverages inhibit markers of inflammation in macrophages and carbohydrate-utilizing enzymes in vitro. Mol. Nutr. Food Res. 2013, 57, 1182-1197.
173. Vendrame, S.; Daugherty, A.; Kristo, A.S.; Riso, P.; Klimis-Zacas, D. Wild blueberry (Vaccinium angustifolium) consumption improves inflammatory status in the obese Zucker rat model of the metabolic syndrome. J. Nutr. Biochem. 2013, 24, 1508-1512.
174. Elek, S.R.; McNair, J.D.; Griffith, G.C. Veratrum viride: Hypotensive and cardiac effects of intravenous use. Calif. Med. 1953, 79, 300-305.
175. Nand, V.; Doggrell, S.A.; Barnett, C.W. Effects of veratridine on the action potentials and contractility of right and left ventricles from normo- and hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1997, 24, 570-576.
176. Singh, B.N.; Saha, C.; Galun, D.; Upreti, D.K.; Bayry, J.; Kaveri, S.V. European Viscum album: A potent phytotherapeutic agent with multifarious phytochemicals, pharmacological properties and clinical evidence. RSC Adv. 2016, 6, 23837-23857.
177. Tang, T.Y.; Li, F.-Z.; Afseth, J. Review of the regulations for clinical research in herbal medicines in USA. Chin. J. Integr. Med. 2014, 20, 883-893.
178. Nelson, H.S. Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Expert Rev. Clin. Immunol. 2014, 10, 1437-1451.
179. Mozaffarian, D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A comprehensive review. Circulation 2016, 133, 187-225.
180. Xiao, J.B.; Högger, P. Dietary polyphenols and type 2 diabetes: Current insights and future perspectives. Curr. Med. Chem. 2015, 22, 23-38.
181. Rohn, S.; van Griensven, L. Grain legumes and further gluten free legumes - Science, technology and impacts on human health. Food Res. Int. 2015, 76, 1-2.
182. Barringer, T.A. Mediterranean diets and cardiovascular disease. Curr. Atheroscler. Rep. 2001, 3, 437-445.
183. Estruch, R.; Ros, E.; Salas-Salvadó, J.; Covas, M.-I.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; Fiol, M.; Lapetra, J.; et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 2013, 368, 1279-1290.
184. Naismith, D.J.; Akinyanju, P.A.; Szanto, S.; Yudkin, J. The effect, in volunteers, of coffee and decaffeinated coffee on blood glucose, insulin, plasma lipids and some factors involved in blood clotting. Nutr. Metabol. 1970, 12, 144-151.
185. Barone, J.J.; Roberts, H.R. Caffeine consumption. Food Chem. Toxicol. 1996, 34, 119-129.
186. Santos, R.M.; Lima, D.R. Coffee consumption, obesity and type 2 diabetes: A mini-review. Eur. J. Nutr. 2016, 55, 1345-1358.
187. Morisco, F.; Lembo, V.; Mazzone, G.; Camera, S.; Caporaso, N. Coffee and liver health. J. Clin. Gastroenterol. 2014, 48 (Suppl. 1), S87-S90.
188. Akash, M.S.; Rehman, K.; Chen, S. Effects of coffee on type 2 diabetes mellitus. Nutrition 2014, 30, 755-763.
189. Zulli, A.; Smith, R.M.; Kubatka, P.; Novak, J.; Uehara, Y.; Loftus, H.; Qaradakhi, T.; Pohanka, M.; Kobyliak, N.; Zagatina, A.; et al. Caffeine and cardiovascular diseases: Critical review of current research. Eur. J. Nutr. 2016, 55, 1331-1343.
190. Ding, M.; Bhupathiraju, S.N.; Satija, A.; van Dam, R.M.; Hu, F.B. Long-term coffee consumption and risk of cardiovascular disease: A systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014, 129, 643-659.
191. Ding, M.; Satija, A.; Bhupathiraju, S.N.; Hu, Y.; Sun, Q.; Han, J.; Lopez-Garcia, E.; Willett, W.; van Dam, R.M.; Hu, F.B. Association of coffee consumption with total and cause-specific mortality in three large prospective cohorts. Circulation 2015, 132, 2305-2315.
192. Natella, F.; Scaccini, C. Role of coffee in modulation of diabetes risk. Nutr. Rev. 2012, 70, 207-217.
193. Vinson, J.A.; Proch, J.; Bose, P.; Muchler, S.; Taffera, P.; Shuta, D.; Samman, N.; Agbor, G.A. Chocolate is a powerful ex vivo and in vivo antioxidant, an antiatherosclerotic agent in an animal model, and a significant contributor to antioxidants in the European and American diets. J. Agric. Food Chem. 2006, 54, 8071-8076.
194. Bonita, J.S.; Mandarano, M.; Shuta, D.; Vinson, J. Coffee and cardiovascular disease: In vitro, cellular, animal, and human studies. Pharmacol. Res. 2007, 55, 187-198.
195. Van Dijk, A.E.; Olthof, M.R.; Meeuse, J.C.; Seebus, E.; Heine, R.J.; van Dam, R.M. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care 2009, 32, 1023-1025.
196. Meng, S.; Cao, J.; Feng, Q.; Peng, J.; Hu, Y. Roles of chlorogenic acid on regulating glucose and lipids metabolism: A review. Evid. Based Complement. Altern. Med. 2013, 2013.
197. Murase, T.; Misawa, K.; Minegishi, Y.; Aoki, M.; Ominami, H.; Suzuki, Y.; Shibuya, Y.; Hase, T. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. Am. J. Physiol. Endocrinol. Metab. 2011, 300, E122-E133.
198. Murase, T.; Yokoi, Y.; Misawa, K.; Ominami, H.; Suzuki, Y.; Shibuya, Y.; Hase, T. Coffee polyphenols modulate whole-body substrate oxidation and suppress postprandial hyperglycaemia, hyperinsulinaemia and hyperlipidaemia. Br. J. Nutr. 2012, 107, 1757-1765.
199. Gramza-Michalowska, A. Caffeine in tea Camellia sinensis - Content, absorption, benefits and risks of consumption. J. Nutr. Health Aging 2014, 18, 143-149.
200. Beecher, G.R.; Warden, B.A.; Merken, H. Analysis of tea polyphenols. Proc. Soc. Exp. Biol. Med. 1999, 220, 267-270.
201. Li, S.; Lo, C.Y.; Pan, M.H.; Lai, C.S.; Ho, C.T. Black tea: Chemical analysis and stability. Food Funct. 2013, 4, 10-18.
202. Gormaz, J.G.; Valls, N.; Sotomayor, C.; Turner, T.; Rodrigo, R. Potential role of polyphenols in the prevention of cardiovascular diseases: Molecular bases. Curr. Med. Chem. 2016, 23, 115-128.
203. Peters, U.; Poole, C.; Arab, L. Does tea affect cardiovascular disease? A meta-analysis. Am. J. Epidemiol. 2001, 154, 495-503.
204. Zhang, C.; Qin, Y.Y.; Wei, X.; Yu, F.F.; Zhou, Y.H.; He, J. Tea consumption and risk of cardiovascular outcomes and total mortality: A systematic review and meta-analysis of prospective observational studies. Eur. J. Epidemiol. 2015, 30, 103-113.
205. Basu, A.; Lucas, E.A. Mechanisms and effects of green tea on cardiovascular health. Nutr. Rev. 2007, 65, 361-375.
206. Sano, M.; Tabata, M.; Suzuki, M.; Degawa, M.; Miyase, T.; Maeda-Yamamoto, M. Simultaneous determination of twelve tea catechins by high-performance liquid chromatography with electrochemical detection. Analyst 2001, 126, 816-820.
207. Chowdhury, A.; Sarkar, J.; Chakraborti, T.; Pramanik, P.K.; Chakraborti, S. Protective role of epigallocatechin-3-gallate in health and disease: A perspective. Biomed. Pharmacother. 2016, 78, 50-59.
208. Chen, G.; Wang, H.; Zhang, X.; Yang, S.-T. Nutraceuticals and functional foods in the management of hyperlipidemia. Crit. Rev. Food Sci. Nutr. 2014, 54, 1180-1201.
209. Magrone, T.; Perez De Heredia, F.; Jirillo, E.; Morabito, G.; Marcos, A.; Serafini, M. Functional foods and nutraceuticals as therapeutic tools for the treatment of diet-related diseases. Can. J. Physiol. Pharmacol. 2013, 91, 387-396.
210. Liu, R.H. Dietary bioactive compounds and their health implications. J. Food Sci. 2013, 78, A18-A25.
211. Badimon, L.; Vilahur, G.; Padro, T. Nutraceuticals and atherosclerosis: Human trials. Cardiovasc. Ther. 2010, 28, 202-215.
212. Zuchi, C.; Ambrosio, G.; Lüscher, T.F.; Landmesser, U. Nutraceuticals in cardiovascular prevention: Lessons from studies on endothelial function. Cardiovasc. Ther. 2010, 28, 187-201.
213. Lacroix, I.M.; Li-Chan, E.C. Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: A natural approach to complement pharmacotherapy in the management of diabetes. Mol. Nutr. Food Res. 2014, 58, 61-78.
214. Hung, H.Y.; Qian, K.; Morris-Natschke, S.L.; Hsu, C.S.; Lee, K.H. Recent discovery of plant-derived anti-diabetic natural products. Nat. Prod. Rep. 2012, 29, 580-606.
215. Gautam, R.; Jachak, S.M. Recent developments in anti-inflammatory natural products. Med. Res. Rev. 2009, 29, 767-820.
216. Hermansen, K.; Dinesen, B.; Hoie, L.H.; Morgenstern, E.; Gruenwald, J. Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: A literature review. Adv. Ther. 2003, 20, 50-78.
217. Vasanthi, H.R.; ShriShriMal, N.; Das, D.K. Phytochemicals from plants to combat cardiovascular disease. Curr. Med. Chem. 2012, 19, 2242-2251.
218. Hardie, D.G. AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013, 62, 2164-2172.
219. Yuan, T.; Nahar, P.; Sharma, M.; Liu, K.; Slitt, A.; Aisa, H.A.; Seeram, N.P. Indazole-type alkaloids from Nigella sativa seeds exhibit antihyperglycemic effects via AMPK activation in vitro. J. Nat. Prod. 2014, 77, 2316-2320.
220. Nguyen, P.H.; Nguyen, T.N.; Dao, T.T.; Kang, H.W.; Ndinteh, D.T.; Mbafor, J.T.; Oh, W.K. AMP-activated protein kinase (AMPK) activation by benzofurans and coumestans isolated from Erythrina abyssinica. J. Nat. Prod. 2010, 73, 598-602.
221. Zimmermann, K.; Baldinger, J.; Mayerhofer, B.; Atanasov, A.G.; Dirsch, V.M.; Heiss, E.H. Activated AMPK boosts the Nrf2/HO-1 signaling axis - A role for the unfolded protein response. Free Radic. Biol. Med. 2015, 88, 417-426.
222. Chen, S. Natural products triggering biological targets - A review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Curr. Drug Targets 2011, 12, 288-301.
223. Jachak, S.M. Cyclooxygenase inhibitory natural products: Current status. Curr. Med. Chem. 2006, 13, 659-678.
224. Chi, Y.S.; Jong, H.G.; Son, K.H.; Chang, H.W.; Kang, S.S.; Kim, H.P. Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: Cyclooxygenases and lipoxygenases. Biochem. Pharmacol. 2001, 62, 1185-1191.
225. Gao, Y.; Zhang, Y.; Zhu, J.; Li, B.; Li, Z.; Zhu, W.; Shi, J.; Jia, Q.; Li, Y. Recent progress in natural products as DPP-4 inhibitors. Future Med. Chem. 2015, 7, 1079-1089.
226. Abe, M.; Akiyama, T.; Nakamura, H.; Kojima, F.; Harada, S.; Muraoka, Y. First synthesis and determination of the absolute configuration of sulphostin, a novel inhibitor of dipeptidyl peptidase IV. J. Nat. Prod. 2004, 67, 999-1004.
227. Saleem, S.; Jafri, L.; ul Haq, I.; Chang, L.C.; Calderwood, D.; Green, B.D.; Mirza, B. Plants Fagonia cretica L. and Hedera nepalensis K. Koch contain natural compounds with potent dipeptidyl peptidase-4 (DPP-4) inhibitory activity. J. Ethnopharmacol. 2014, 156, 26-32.
228. Schmitt, C.A.; Dirsch, V.M. Modulation of endothelial nitric oxide by plant-derived products. Nitric Oxide 2009, 21, 77-91.
229. Waldbauer, K.; Seiringer, G.; Nguyen, D.L.; Winkler, J.; Blaschke, M.; McKinnon, R.; Urban, E.; Ladurner, A.; Dirsch, V.M.; Zehl, M.; et al. Triterpenoic acids from apple pomace enhance the activity of the endothelial nitric oxide synthase (eNOS). J. Agric. Food Chem. 2016, 64, 185-194.
230. Xia, N.; Pautz, A.; Wollscheid, U.; Reifenberg, G.; Förstermann, U.; Li, H. Artichoke, cynarin and cyanidin downregulate the expression of inducible nitric oxide synthase in human coronary smooth muscle cells. Molecules 2014, 19, 3654-3668.
231. Shen, K.; Leung, S.W.; Ji, L.; Huang, Y.; Hou, M.; Xu, A.; Wang, Z.; Vanhoutte, P.M. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Biochem. Pharmacol. 2014, 88, 66-74.
232. Auger, C.; Chaabi, M.; Anselm, E.; Lobstein, A.; Schini-Kerth, V.B. The red wine extract-induced activation of endothelial nitric oxide synthase is mediated by a great variety of polyphenolic compounds. Mol. Nutr. Food Res. 2010, 54 (Suppl. 2), S171-S183.
233. Leung, K.W.; Cheng, Y.K.; Mak, N.K.; Chan, K.K.; Fan, T.P.; Wong, R.N. Signaling pathway of ginsenoside-Rg1 leading to nitric oxide production in endothelial cells. FEBS Lett. 2006, 580, 3211-3216.
234. Ndiaye, M.; Chataigneau, M.; Lobysheva, I.; Chataigneau, T.; Schini-Kerth, V.B. Red wine polyphenol-induced, endothelium-dependent NO-mediated relaxation is due to the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of endothelial NO-synthase in the isolated porcine coronary artery. FASEB J. 2005, 19, 455-457.
235. Golan-Goldhirsh, A.; Gopas, J. Plant derived inhibitors of NF-κB. Phytochem. Rev. 2014, 13, 107-121.
236. Chan, M.M. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem. Pharmacol. 1995, 49, 1551-1556.
237. Siedle, B.; Garcia-Pineres, A.J.; Murillo, R.; Schulte-Mönting, J.; Castro, V.; Rüngeler, P.; Klaas, C.A.; da Costa, F.B.; Kisiel, W.; Merfort, I. Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-κB. J. Med. Chem. 2004, 47, 6042-6054.
238. Fakhrudin, N.; Waltenberger, B.; Cabaravdic, M.; Atanasov, A.G.; Malainer, C.; Schachner, D.; Heiss, E.H.; Liu, R.; Noha, S.M.; Grzywacz, A.M.; et al. Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo. Br. J. Pharmacol. 2014, 171, 1676-1686.
239. Kopp, E.; Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994, 265, 956-959.
240. Kumar, H.; Kim, I.S.; More, S.V.; Kim, B.W.; Choi, D.K. Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat. Prod. Rep. 2014, 31, 109-139.
241. Balogun, E.; Hoque, M.; Gong, P.; Killeen, E.; Green, C.J.; Foresti, R.; Alam, J.; Motterlini, R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 2003, 371, 887-895.
242. Heiss, E.H.; Tran, T.V.; Zimmermann, K.; Schwaiger, S.; Vouk, C.; Mayerhofer, B.; Malainer, C.; Atanasov, A.G.; Stuppner, H.; Dirsch, V.M. Identification of chromomoric acid C-I as an Nrf2 activator in Chromolaena odorata. J. Nat. Prod. 2014, 77, 503-508.
243. Ahn, Y.H.; Hwang, Y.; Liu, H.; Wang, X.J.; Zhang, Y.; Stephenson, K.K.; Boronina, T.N.; Cole, R.N.; Dinkova-Kostova, A.T.; Talalay, P.; et al. Electrophilic tuning of the chemoprotective natural product sulforaphane. Proc. Natl. Acad. Sci. USA 2010, 107, 9590-9595.
244. Wang, L.; Waltenberger, B.; Pferschy-Wenzig, E.M.; Blunder, M.; Liu, X.; Malainer, C.; Blazevic, T.; Schwaiger, S.; Rollinger, J.M.; Heiss, E.H.; et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): A review. Biochem. Pharmacol. 2014, 92, 73-89.
245. Atanasov, A.G.; Blunder, M.; Fakhrudin, N.; Liu, X.; Noha, S.M.; Malainer, C.; Kramer, M.P.; Cocic, A.; Kunert, O.; Schinkovitz, A.; et al. Polyacetylenes from Notopterygium incisum - New selective partial agonists of peroxisome proliferator-activated receptor-gamma. PLoS ONE 2013, 8, e61755.
246. Atanasov, A.G.; Wang, J.N.; Gu, S.P.; Bu, J.; Kramer, M.P.; Baumgartner, L.; Fakhrudin, N.; Ladurner, A.; Malainer, C.; Vuorinen, A.; et al. Honokiol: A non-adipogenic PPARgamma agonist from nature. Biochim. Biophys. Acta 2013, 1830, 4813-4819.
247. Fakhrudin, N.; Ladurner, A.; Atanasov, A.G.; Heiss, E.H.; Baumgartner, L.; Markt, P.; Schuster, D.; Ellmerer, E.P.; Wolber, G.; Rollinger, J.M.; et al. Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma. Mol. Pharmacol. 2010, 77, 559-566.
248. Puhl, A.C.; Bernardes, A.; Silveira, R.L.; Yuan, J.; Campos, J.L.; Saidemberg, D.M.; Palma, M.S.; Cvoro, A.; Ayers, S.D.; Webb, P.; et al. Mode of peroxisome proliferator-activated receptor gamma activation by luteolin. Mol. Pharmacol. 2012, 81, 788-799.
249. Weidner, C.; de Groot, J.C.; Prasad, A.; Freiwald, A.; Quedenau, C.; Kliem, M.; Witzke, A.; Kodelja, V.; Han, C.T.; Giegold, S.; et al. Amorfrutins are potent antidiabetic dietary natural products. Proc. Natl. Acad. Sci. USA 2012, 109, 7257-7262.
250. Wang, L.-J.; Jiang, B.; Wu, N.; Wang, S.-Y.; Shi, D.-Y. Natural and semisynthetic protein tyrosine phosphatase1B (PTP1B) inhibitors as anti-diabetic agents. RSC Adv. 2015, 5, 48822-48834.
251. Jiang, C.S.; Liang, L.F.; Guo, Y.W. Natural products possessing protein tyrosine phosphatase 1B (PTP1B) inhibitory activity found in the last decades. Acta Pharmacol. Sin. 2012, 33, 1217-1245.
252. Heiss, E.H.; Baumgartner, L.; Schwaiger, S.; Heredia, R.J.; Atanasov, A.G.; Rollinger, J.M.; Stuppner, H.; Dirsch, V.M. Ratanhiaphenol III from Ratanhiae radix is a PTP1B inhibitor. Planta Med. 2012, 78, 678-681.
253. Feng, Y.; Carroll, A.R.; Addepalli, R.; Fechner, G.A.; Avery, V.M.; Quinn, R.J. Vanillic acid derivatives from the green algae Cladophora socialis as potent protein tyrosine phosphatase 1B inhibitors. J. Nat. Prod. 2007, 70, 1790-1792.
254. Yoon, G.; Lee, W.; Kim, S.N.; Cheon, S.H. Inhibitory effect of chalcones and their derivatives from Glycyrrhiza inflata on protein tyrosine phosphatase 1B. Bioorg. Med. Chem. Lett. 2009, 19, 5155-5157.
255. Werz, O. Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin. Planta Med. 2007, 73, 1331-1357.
256. Oettl, S.K.; Gerstmeier, J.; Khan, S.Y.; Wiechmann, K.; Bauer, J.; Atanasov, A.G.; Malainer, C.; Awad, E.M.; Uhrin, P.; Heiss, E.H.; et al. Imbricaric acid and perlatolic acid: Multi-targeting anti-inflammatory depsides from Cetrelia monachorum. PLoS ONE 2013, 8, e76929.
257. De la Puerta, R.; Ruiz Gutierrez, V.; Hoult, J.R. Inhibition of leukocyte 5-lipoxygenase by phenolics from virgin olive oil. Biochem. Pharmacol. 1999, 57, 445-449.
258. Winekenstädde, D.; Angelis, A.; Waltenberger, B.; Schwaiger, S.; Tchoumtchoua, J.; König, S.; Werz, O.; Aligiannis, N.; Skaltsounis, A.-L.; Stuppner, H. Phytochemical profile of the aerial parts of Sedum sediforme and anti-inflammatory activity of myricitrin. Nat. Prod. Commun. 2015, 10, 83-88.
259. Endo, A. A historical perspective on the discovery of statins. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2010, 86, 484-493.
260. Tanzawa, K.; Kuroda, M.; Endo, A. Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutarylcoenzyme A reductase by the antibiotic citrinin. Biochim. Biophys. Acta 1977, 488, 97-101.
261. Endo, A.; Kuroda, M. Citrinin, an inhibitor of cholesterol synthesis. J. Antibiot. Tokyo 1976, 29, 841-843.
262. Endo, A.; Kuroda, M.; Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. Tokyo 1976, 29, 1346-1348.
263. Endo, A.; Kuroda, M.; Tanzawa, K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976, 72, 323-326.
264. Endo, A.; Tsujita, Y.; Kuroda, M.; Tanzawa, K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 1977, 77, 31-36.
265. Alberts, A.W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Rothrock, J.; Lopez, M.; Joshua, H.; Harris, E.; et al. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 1980, 77, 3957-3961.
266. Endo, A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J. Antibiot. Tokyo 1979, 32, 852-854.
267. Endo, A. A gift from nature: The birth of the statins. Nat. Med. 2008, 14, 1050-1052.
268. Grundy, S.M. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia. Nat. Rev. Cardiol. 2016, 13, 74-75.
269. Bailey, C.; Day, C. Metformin: Its botanical background. Pract. Diab. Int. 2004, 21, 115-117.
270. Müller, H.; Reinwein, H. Pharmacology of galegin. Arch. Exp. Pathol. Pharmakol. 1927, 125, 212-228.
271. Tanret, G. An alkaloid extracted from Galega officinalis. Compt. Rend. 1914, 158, 1182-1184.
272. Barger, G.; White, F.D. The constitution of galegine. Biochem. J. 1923, 17, 827-835.
273. Watanabe, C.K. Studies in the metabolic changes induced by administration of guanidine bases. I. The influence of injected guanidine hydrochloride upon blood sugar content. J. Biol. Chem. 1918, 33, 253-265.
274. Bailey, C.; Campbell, I.; Chan, J.; Davidson, J.; Howlett, H.; Ritz, P. Metformin: The Gold Standard. A Scientific Handbook; Wiley: Chichester, UK, 2007.
275. Cusi, K.; DeFronzo, R.A. Metformin: A review of its metabolic effects. Diabetes Rev. 1998, 6, 89-131.